RYZB

Rayzebio Inc

A biotechnology company that makes cancer drugs delivering radioactive "rays" directly to tumor cells while sparing healthy tissue — its lead drug, RYZ101, targets neuroendocrine tumors. Founded in 2020 after its founders realized the field of targeted radiopharmaceuticals was surprisingly under-competed, it was acquired by Bristol Myers Squibb in 2024. Its name blends "rays" and "raise," a nod to lifting survival, and its Indianapolis plant ships fragile doses to hospitals within days.

No 8-K or 6-K filings recorded.